Evidence map›Paper›PMID 31049360›Full record

ArticleJournal of immunology research2019

Enhanced Antitumor Immune Response in 2'-5' Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy.

Chan Kyu Sim, Jung Hoon Lee, In-Jeoung Baek, Sang-Wook Lee, Myeong Sup Lee

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Chan Kyu SimLaboratory of Molecular Immunology and Medicine, Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Jung Hoon LeeLaboratory of Molecular Immunology and Medicine, Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
In-Jeoung BaekDepartment of Convergence Medicine, Asan Institutes for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Republic of Korea.
Sang-Wook LeeDepartment of Radiation Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.
Myeong Sup LeeLaboratory of Molecular Immunology and Medicine, Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Republic of Korea.ORCID 0000-0002-8144-824X
Ulsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type I interferon (IFN-I) plays a critical role in the antitumor immune response. In our previous study, we showed that IFN-I-inducible 2'-5' oligoadenylate synthetase-like 1 (OASL1) negatively regulated IFN-I production upon tumor challenge similar to that of viral infection. Thus, OASL1-deficient (

Indexed as

2',5'-Oligoadenylate SynthetaseAnimalsAntineoplastic AgentsCisplatinInterferon-gammaInterferon Type ILung NeoplasmsMiceMice, Inbred C57BLMice, KnockoutMolecular Targeted TherapyNeoplasm Metastasis2',5'-Oligoadenylate SynthetaseAntineoplastic AgentsCisplatinInterferon-gammaInterferon Type IOasl1 protein, mouse

Identifiers

PMID31049360
PMCPMC6462330
OpenAlexW2930276540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.